Skip to content

Repurposing Gastric Cancer Biomarkers for Mucinous Ovarian Carcinoma: ERBB2 and Claudin 18.2 as Therapeutic Targets.

Sep 2026 · International Journal of Gynecological Pathology · 0 citations · 44 references
Medicine

TL;DR

While the immunohistochemical panel developed is of insufficient diagnostic accuracy to distinguish MOC from GA, consideration should be given to include MOC in clinical basket trials targeting ERBB2 and Claudin 18.2.

Abstract

Mucinous ovarian carcinomas (MOCs) have an upper-gastrointestinal cell phenotype (CK7+/SATB2-) similar to pancreatic ductal adenocarcinoma (PDAC) and gastric adenocarcinoma (GA). We aimed to develop an immunohistochemical panel that accurately discriminates MOC from GA. A secondary objective was to compare molecular and targetable tissue-based biomarkers across MOC, GA, and PDAC. Immunohistochemistry was performed on tissue microarrays representing 103 MOC, 265 PDAC, and 159 GA for markers of cell lineage (CK17, MEP1A, PAX8, CDX2, and HIK1083), key molecular alterations [TP53, Mismatch Repair deficiency (MMRd), CTNNB1, ARID1A, and SMAD4], as well as potential antibody targets (ERBB2 and Claudin 18.2). In situ hybridization was performed for Epstein-Barr virus-encoded RNA. A lasso-penalized nominal logistic regression model discriminated the 3 entities with low overall accuracy [77.8%, area under the curve (AUC)=0.91]. Discrimination from others was highest for PDAC (AUC=0.93) and MOC (AUC=0.92), but lowest for GA (AUC=0.87), and MOC was more similar to GA than to PDAC. MOC more frequently showed Claudin 18.2 PS2+ high (42%) and ERBB2 IHC3+ (25%) than GA (Claudin 18.2, 25%; ERBB2, 3%; MMRd, 19%) and PDAC (Claudin 18.2, 10%; ERBB2, 0%; MMRd, 2%). At least 1 potentially targetable alteration was present in 60% of MOC, 43% of GA, and 12% of PDAC. While our marker panel is of insufficient diagnostic accuracy to distinguish MOC from GA, based on the similarity between MOC and GA, consideration should be given to include MOC in clinical basket trials targeting ERBB2 and Claudin 18.2.

View source

Similar papers

Open access Sep 2026

Claudin 18 is not a biomarker for breast mucinous tumor

Background: Breast mucinous cystadenocarcinoma (BMCA) is an exceptionally rare malignancy that may resemble mucinous neoplasms of the pancreas, ovary, lung, and colorectum. Claudin 18 (CLDN18), particularly its gastric-associated isoform CLDN18.2, is an emerging therapeutic target; however, CLDN18 immunoreactivity has...

Shih-En Lin, Shih-Jheng Liou, Wan-Ching Chen et al. · 0 citations
Review Open access Oct 2026

CLDN18.2 in colorectal mucinous adenocarcinoma: a lineage-associated biomarker and emerging translational target

Current evidence supports CLDN18.2 as a candidate biomarker for biomarker-enriched investigation, not as an established therapeutic target in CMA, and proposes a framework centered on lineage reprogramming, antigen enrichment, assay standardization, and therapeutic translation.

Wei Yu, Sheng-Tian Wei, Shi-Qing Wan et al. · 0 citations
Open access Oct 2026

OTI1H1-Defined MAGEA3-Directed Immunoreactivity and Survival in Pancreatic Ductal Adenocarcinoma: A Single-Center Study

Background/Objectives: Melanoma-associated antigen A3 (MAGEA3) is a cancer–testis antigen with potential biological and prognostic relevance in pancreatic ductal adenocarcinoma (PDAC). This study evaluated the association between OTI1H1-defined MAGEA3-directed immunoreactivity and clinicopathological characteristics an...

Goran Glavčić, Marin Glavčić, S. Janković et al. · 0 citations
Open access Sep 2026

TROP2 expression in gastric and GEJ adenocarcinomas: associations with clinicopathological features, biomarkers, and treatment outcomes

Background Trophoblast cell surface antigen 2 (TROP2) is frequently expressed in solid tumors, including gastric cancer (GC) and gastroesophageal junction cancer (GEJC), but its distribution and clinical relevance remain unclear. Patients and methods We analyzed patients with GC/GEJC who underwent prospective multibiom...

Y. Tong, I. Nakayama, N. Sakamoto et al. · 0 citations
Open access Sep 2026

Immunohistochemical stratification of bladder small cell carcinoma reveals two major phenotypes with distinct therapeutic biomarker profiles.

Low membranous Nectin-4 expression and preferential DLL3 and SLFN11 expression in High-NE tumours support further investigation of alternative therapeutic strategies, and SmCCB may be stratified into two IHC-defined phenotypic groups with distinctive neuroendocrine differentiation and therapeutic biomarker profiles.

N. Tenace, M. Colecchia, A. Hartmann et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.